MedTrace Logo

Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs. Triple Therapy With a Boosted Protease Inhibitor

NCT01166477 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2013-03-20

No results posted yet for this study

Summary

The Study will help to compare the Quality of Life for those HIV patients that are on monotherapy with LPV/r Vs. triple therapy with a boosted protease inhibitor

Conditions

  • HIV Infection

Interventions

DRUG

Lopinavir and ritonavir

The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid

DRUG

Triple therapy with ritonavir

The patients will continue to take their usual triple therapy, as established in the summary of product characteristics

Sponsors & Collaborators

  • Sociedad Andaluza de Enfermedades Infecciosas

    lead NETWORK

Principal Investigators

  • Juan Pasquau, MD · Sociedad Andaluza de Enfermedades Infecciosas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01166477 on ClinicalTrials.gov